Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq: HCM) (AIM: HCM) (HKEX: 13) announced on Monday that results from its Phase III trial ESLIM-01 of sovleplenib (HMPL-523) for primary immune thrombocytopenia (ITP) have been published in The Lancet Haematology. Presented at the European Hematology Association 2024 Hybrid Congress on 14 June 2024, the study demonstrated a 48.4% durable response rate with sovleplenib compared to 0% with placebo.
Sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), showed consistent clinical benefits regardless of prior therapies or TPO/TPO-RA exposure. The trial involved 188 adult patients with primary ITP, showcasing a significant improvement in durable response and quality of life, with a median response time of eight days compared to 30 days for placebo.
The study's primary endpoint was met with 48.4% of patients achieving durable responses with sovleplenib, compared to none with placebo (p
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study